PACAP antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10822408-B2
Application number	US-201616063152-A
Country	US
Kind code	B2
Filing date	Dec 15, 2016
Priority date	Dec 15, 2015
Publication date	Nov 3, 2020
Grant date	Nov 3, 2020

Abstract

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

First claim

What is claimed:

1. A method for inhibiting activation of human PAC1 receptor in a patient having a headache condition comprising administering to the patient an effective amount of a monoclonal antibody or binding fragment thereof, wherein the monoclonal antibody or binding fragment specifically binds to human pituitary adenylate cyclase-activating polypeptide (PACAP) and inhibits PACAP38-induced activation of human PAC1 receptor, wherein the monoclonal antibody or binding fragment comprises a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein:
(a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 30, 35, and 40, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 45, 51, and 56, respectively;
(b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 31, 36, and 41, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 46, 52, and 57, respectively; or
(c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 30, 35, and 40, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 47, 51, and 58, respectively.

2. The method of claim 1 , wherein the headache condition is migraine.

3. The method of claim 2 , wherein the migraine is episodic migraine or chronic migraine.

4. The method of claim 1 , wherein the headache condition is cluster headache.

5. The method of claim 1 , wherein the monoclonal antibody or binding fragment binds an epitope within residues 28 to 37 of human PACAP38 (SEQ ID NO: 1).

6. The method of claim 1 , wherein the monoclonal antibody or binding fragment binds an epitope within residues 34 to 38 of human PACAP38 (SEQ ID NO: 1).

7. The method of claim 1 , wherein the monoclonal antibody or binding fragment thereof binds to a polypeptide consisting of the sequence of SEQ ID NO: 4, but does not significantly bind to a polypeptide consisting of the sequence of SEQ ID NO: 5.

8. The method of claim 1 , wherein the monoclonal antibody or binding fragment thereof binds to a polypeptide consisting of the sequence of SEQ ID NO: 4 with a binding affinity at least 2-fold greater than that for a polypeptide consisting of the sequence of SEQ ID NO: 115.

9. The method of claim 1 , wherein the monoclonal antibody or binding fragment thereof binds to a polypeptide consisting of the sequence of SEQ ID NO: 4.

10. The method of claim 1 , wherein the monoclonal antibody or binding fragment thereof binds to a polypeptide consisting of the sequence of SEQ ID NO: 126.

11. The method of claim 1 , wherein the monoclonal antibody or binding fragment does not significantly inhibit the binding of PACAP27 to human PAC1 receptor.

12. The method of claim 1 , wherein the monoclonal antibody or binding fragment inhibits PACAP38-induced activation of human PAC1 receptor with an IC50 less than 1 nM as measured by a cell-based cAMP assay.

13. The method of claim 1 , wherein the monoclonal antibody or binding fragment does not significantly inhibit PACAP27-induced activation of human PAC1 receptor.

14. The method of claim 1 , wherein the monoclonal antibody or binding fragment thereof is a humanized antibody or binding fragment thereof.

15. The method of claim 14 , wherein the humanized monoclonal antibody comprises an Fc region from a human IgG1, IgG2, IgG3 or IgG4 antibody.

16. The method of claim 1 , wherein the monoclonal antibody or binding fragment binds an epitope within residues 28 to 38 of human PACAP38 (SEQ ID NO: 1).

17. An isolated monoclonal antibody or binding fragment thereof that specifically binds to human PACAP and inhibits PACAP38-induced activation of human PAC1 receptor, wherein the monoclonal antibody or binding fragment comprises a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein:
(a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 30, 35, and 40, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 45, 51, and 56, respectively;
(b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 31, 36, and 41, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 46, 52, and 57, respectively; or
(c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 30, 35, and 40, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 47, 51, and 58, respectively.

18. The isolated monoclonal antibody or binding fragment thereof of claim 17 , wherein the monoclonal antibody or binding fragment thereof is a humanized antibody or binding fragment thereof.

19. The isolated monoclonal antibody or binding fragment thereof of claim 18 , wherein the humanized monoclonal antibody comprises an Fc region from a human IgG1, IgG2, IgG3 or IgG4 antibody.

20. A composition comprising the monoclonal antibody or binding fragment thereof of claim 17 and a pharmaceutically acceptable diluent, excipient, or carrier.

21. A method for treating or reducing the occurrence of a headache condition in a patient in need thereof comprising administering to the patient an effective amount of a monoclonal antibody or binding fragment thereof of claim 17 .

22. The method of claim 21 , wherein the headache condition is migraine or cluster headache.

23. The method of claim 21 , wherein the monoclonal antibody or binding fragment thereof is administered to the patient as a prophylactic treatment.

Assignees

• Amgen Inc

Inventors

• Hamburger Agnes E
• Xu Cen
• Sun Hong
• Shih Yuan D
• Weeraratne Dohan

Classifications

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title